Company Overview and News
KUALA LUMPUR (Oct 2): The FBM KLCI was hard pressed to find a firm footing in the morning session and remained below the crucial 1,800-point level at the midday break, as regional markets retreated.
HLFBF BRDBF UPBMF 1082 5168 2089 5256 5255 9334 5199 5210 4634 5139 4456 3026 0900 0026 7108 2836 HIPEF GEBHF HRGHY
KUALA LUMPUR: Upstream activities are increasing in tandem with crude oil prices that are climbing steadily. While things are looking up in the oil and gas (O&G) industry, many domestic O&G companies are still bogged down by high borrowings and finance costs.
5115 BRDBF 7108 BSMAF 5255 5210 1818
KUALA LUMPUR (Aug 29): While this marks its third consecutive loss-making quarter, Icon Offshore Bhd saw its net loss narrow to RM4.66 million in the second quarter ended June 30, 2018 (2QFY18), from RM6.56 million a year ago, on lower tax expense.
KUALA LUMPUR (July 25): The FBM KLCI advanced 0.12% at the midday break, tracking regional gains, lifted by select index-linked blue chips.
7052 UPBMF 5681 BATS 4162 2089 5255 9334 5199 4588 5347 1201 3301 8613 TNABY 2836 TNABF HIPEF GEBHF 3719
KUALA LUMPUR (July 25): The FBM KLCI clawed into positive territory at mid-morning but remained somewhat muted against the backdrop of the positive regional markets.
HLFBF 7052 UPBMF 4065 1082 9679 5245 2089 5255 5436 1201 3301 8613 2739 2836
KUALA LUMPUR (July 6): The FBM KLCI fell 0.77% at midday break as regional markets slumped, as U.S. tariffs against China took effect this afternoon.
PBLOF UPBMF 4065 6399 5681 1295 2089 7055 7154 5255 7277 CIMDF KLKBY 5139 1023 2445 0900 8613 0026 6888 2216 AXXTF
KUALA LUMPUR (July 6): The FBM KLCI fell 0.37% art mid-morning today, dragged by index-linked banking stocks against the backdrop of mixed regional markets.
MLYBY MLYNF UPBMF 4065 BATS 4162 2089 7055 7154 5255 CIMDF 1155 5139 1023 0900 0026 6888 5819 AXXTF
KUALA LUMPUR (July 2): AllianceDBS Research said Icon Offshore Bhd (Icon) had on June 29 gapped up to cross over the 14 sen hurdle.
KUALA LUMPUR (June 29): The FBM KLCI staged a technical rebound today to snap a four-day losing streak, finishing 25.82 points or 1.55% higher at 1,691.50 points, in tandem with the regional markets.
KUALA LUMPUR (June 29): The FBM KLCI briefly crossed the 1,700-point level in the morning session today before paring some gains to close 1.8% higher at the break.
7251 MLYNF 7113 TPGVF 2089 5255 KLKBY 1023 5347 TNABY 2836 1929 HRGHY MLYBY UPBMF 5168 1481 CIMDF TGLVY 5139 1155 5216 2445 0900 TNABF
KUALA LUMPUR (June 29): The FBM KLCI rose 1.38% at mid-morning today on 1H18 window-dressing activities, led by gains in Tenaga Nasional Bhd.
7172 7251 SPMXF 8621 7113 TPGVF 7765 5168 1481 5255 TGLVY 5139 KLKBY 2445 5216 SPMXY 5347 3026 0900 TNABY TNABF 1929 HRGHY
KUALA LUMPUR (June 29): Icon Offshore Bhd surged 17.39% in active trade this morning after it bagged contracts valued at RM275 million from oil and gas (O&G) companies to provide offshore support vessels (OSVs) for their production operations in Malaysian waters.
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...